Industrial Policy & Trade Monitor· 2663 actions· ✨ 89 recent

On June 8, 2026, the US Department of Defense published its annual update to the Section 1260H Chinese Military Companies (CMIC) list, adding 65 entities (17 new parent companies and 48 subsidiaries), bringing the total to approximately 188–200 designated entities. Major additions span EV and battery manufacturing (BYD, NIO, CATL), consumer internet (Alibaba, Baidu, Tencent), semiconductors (SMIC, YMTC, CXMT), solar (JA Solar, Trina Solar), biotech (BGI Genomics, WuXi AppTec), drones/robotics (DJI, Unitree, RoboSense), and telecoms (TP-Link). Effective June 30, 2026, DoD is prohibited from procuring goods, services, or technology directly from listed entities; effective June 30, 2027, the ban extends to indirect supply-chain procurement through prime contractors and all sub-tiers.

On 23 May 2026 President Javier Milei, Economy Minister Luis Caputo, and Chief of Staff Manuel Adorni announced the "Régimen de Incentivo para Grandes Inversiones en Nuevas Industrias" (Super RIGI), and on 26 May 2026 submitted the bill (Mensaje 181/2026, expediente 0005-PE-2026) to the Cámara de Diputados — pending Congressional approval as of filing. The regime applies a US$1 billion minimum investment threshold (with ≥20% committed in the first two years), a 15% corporate income tax rate (vs 25% under the base 2024 RIGI), accelerated depreciation of 60%/20%/20% over three years, immediate export-duty exemption (vs year 3 under RIGI), import-tariff exemption, and 30-year regulatory stability across tax, customs, social security, and FX matters. A progressive FX-liberalisation schedule allows 20% / 40% / 100% free disposal of export-generated foreign currency in years 1 / 2 / 3+. Target sectors are industries that "do not currently exist or are in experimental/pilot phase in Argentina," including semiconductors, AI data centres, advanced biotech, 100% electric vehicles, lithium value chain (downstream processing, cathode, battery), green hydrogen, solar panels, wind turbines, onshore LNG, SMR nuclear, aerospace, uranium value chain, potassium and phosphorus fertilisers, and new petrochemicals.

On 8 May 2026 China's National Health Commission released a public consultation draft proposing material amendments to the 2023 Implementation Rules for the Administrative Regulations on Human Genetic Resources, with a comment deadline of 7 June 2026. The draft narrows the statutory "foreign party" definition to a bright-line 50% equity/voting threshold (excluding VIE-structured entities), restricts "HGR Information" strictly to nucleic-acid sequence data (excluding clinical, imaging, and metabolic data), removes the separate Article 37 security-review requirement for sensitive HGR datasets, and introduces a same-day or next-working-day fast-track confirmation for international clinical trials not involving HGR information export.

The Decreto para la Autorización Inmediata de Inversiones, published in Mexico's Diario Oficial de la Federación on 4 May 2026, creates a streamlined investment-authorization mechanism under President Sheinbaum's Plan México strategy. The decree establishes an Investment Committee — composed of the Secretariats of Economía, Hacienda, SEMARNAT, SCT, Energía, and Bienestar — mandated to issue authorization certificates within 30 business days for qualifying projects, replacing the historic 6–18-month multi-agency backlog. Eligibility covers three tiers: projects in designated Polos de Desarrollo Económico para el Bienestar (Welfare Development Poles), investments of MXN 2 billion (≈USD 100M) or more, and projects in strategic sectors (semiconductors, EV batteries, critical minerals, automotive supply chain, medical devices, biotech, aerospace). This is the procedural- acceleration arm of Plan México, structurally distinct from the January 2025 Plan México tax-incentive decree (the fiscal arm), and operationalises the February 2026 Plan México expansion announced by Sheinbaum.

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

South Korea's 13th National Strategic Technology Special Committee (chaired by MSIT) adopted the 2026 Annual Implementation Plan for the First Basic Plan for National Strategic Technology Development (2024–2028), committing KRW 8.6 trillion in 2026 R&D investment — a ~30% YoY increase from KRW 6.5 trillion in 2025 — across 19 NEXT strategic-technology fields encompassing AI, semiconductors, quantum, displays, and secondary batteries, coordinated across 23 ministries. The plan is supplemented by KRW 46.6 trillion in policy finance delivered through Korea Development Bank (KDB), Industrial Bank of Korea (IBK), Korea Credit Guarantee Fund (KCGF), and Korea Technology Finance Corporation (KOTEC), providing the horizontal funding-coordination architecture that operationalises all sector-specific Korean strategic-technology legislative instruments.

The US Department of Commerce published its final affirmative determination of sales at less-than-fair-value in the antidumping investigation of animal feed-grade L-lysine (lysine) from China (case A-570-215) on 23 July 2026, following a preliminary determination published 6 March 2026 (91 FR 11030). Commerce found a China-wide weighted-average dumping margin of 139.83% (cash deposit rate 139.65% after subsidy-offset adjustment), based on adverse facts available after Commerce found Zhengzhou Longgu Trading Co., the sole company with a calculated margin, and the Eppen Group group of producers/exporters uncooperative and ineligible for a separate rate in the final determination. A group of separate-rate companies — including Anhui BBCA Biochemical, Heilongjiang Wanlirunda Biotechnology, and others exporting through trading intermediaries such as Agromate Sg, Ainore (Tianjin), and Aollen Biotech — received a 73.55% dumping margin (73.37% cash deposit rate). The order covers lysine regardless of form (HCl, sulfate, liquid) under HTSUS 2922.41.0090 and related subheadings. A companion countervailing-duty investigation (preliminary 22 January 2026, 91 FR 2745) was finalized the same day; suspension of liquidation runs from 6 March 2026, with a final AD order contingent on an ITC injury determination due within 45 days of the final LTFV finding.

Gujarat Chief Minister Bhupendra Patel launched the Gujarat Science, Technology and Innovation (STI) Policy 2026–2031 on 1 March 2026 at the SemiConnect 2026 Conference in Gandhinagar, establishing a five-year ₹1,000 crore Swadeshi Anusandhan Fund (Indigenous Innovation Fund) for domestic R&D across strategic sectors including AI, semiconductors, quantum technologies, biotechnology, green energy, and defence. The policy targets state STI expenditure of 1% of GSDP by 2030, creation of 1 lakh skilled research professionals, 1,000+ IP filings annually, and builds three Gujarat Rajya Research and Innovation Cluster (GRRIC) corridors to anchor the state's growing semiconductor manufacturing ecosystem.

India's DGFT issued Notification No. 56/2025-26 on 29 January 2026, amending the import policy under Chapter 29 of ITC (HS) 2022 to impose minimum import prices (MIPs) on three antibiotic Active Pharmaceutical Ingredients (APIs): Penicillin G-potassium (₹2,216/kg CIF), Amoxycillin trihydrate (₹2,733/kg CIF), and 6-Aminopenicillanic Acid/6-APA (₹3,405/kg CIF). Imports below these price floors are reclassified from "Free" to "Restricted" status, requiring a DGFT import authorisation before Customs clearance. The measure takes immediate effect and is valid for approximately ten months (until 30 November 2026), with an implied renewal pathway. It is explicitly aimed at preventing very-low-priced imports and supporting domestic manufacturers built under the PLI Bulk Drugs scheme, targeting China's dominant position in global antibiotic-fermentation supply.

The US Department of Commerce published its final affirmative countervailing-duty (CVD) determination on animal feed-grade L-lysine from China (case C-570-216) on 23 July 2026, the companion subsidy proceeding to the parallel antidumping case (A-570-215) finalized the same day. Commerce found Heilongjiang Wanlirunda Biotechnology Co., Ltd. and Shouguang Golden-land Industry & Trading Co., Ltd. received countervailable subsidies at 82.11%, while Inner Mongolia Eppen Biotech Co., Ltd. and all other Chinese producers/exporters were assigned a 48.21% subsidy rate. The preliminary CVD determination, published 22 January 2026, set the initial cash-deposit rates and suspension of liquidation; the final determination confirmed and aligned the case with the AD final determination for a joint ITC injury vote.

On 29 December 2025, Brazil's national development bank BNDES approved R$1.13 billion (~USD 205 million) in financing for Companhia Siderúrgica Nacional (CSN) to modernise three industrial plants at the Usina Presidente Vargas in Volta Redonda (RJ). R$625.8 million comes through the Finem credit line for sintering-plant emissions-control upgrades (new electrostatic precipitators and bag filters) that partly reimburse investments CSN made since 2023 to satisfy a Term of Adjustment of Conduct (TAC) with Rio de Janeiro's state environmental agency (INEA). A further R$500 million comes through the BNDES Mais Inovação programme for innovative machinery, IT equipment and IoT technology services. BNDES states the financing "fortalece a cadeia produtiva nacional de equipamentos" (strengthens the national equipment supply chain), giving the operation a domestic-content-preference dimension alongside its environmental/innovation financing purpose.

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 3, "Several Measures of Huangpu District on Promoting Brain-Computer Interface Innovation and Transformation Services (Trial)" (informally the "BCI Service 10 Provisions"), effective 24 January 2026 and valid through 31 December 2027. The measures subsidize BCI core- technology R&D and district co-funding of national/municipal projects (up to CNY 2m, 1:1 district match), shared innovation-platform construction (up to 30% of investment, capped CNY 2m), registered medical-device commercialisation (up to 40% of R&D cost, capped CNY 5m/ year per entity), application-demonstration scenarios (up to 30% of investment, capped CNY 2m), enterprise-growth and unicorn/gazelle recognition rewards (CNY 20k-100k), industrial-park operator support (up to CNY 2m/year), equity-financing support (up to 10% of R&D cost, capped CNY 2m, for firms with ≥CNY 20m in equity funding), and international BCI conference/event sponsorship (up to 30%, capped CNY 500k).

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 2, "Several Measures on Focusing on Translational Medicine to Accelerate Industry-Medicine Integration Innovation and Development," effective 30 days after promulgation (4 February 2026 per Global Trade Alert tracking) and valid through 31 December 2027. The measures subsidize cell-and-gene therapy, mRNA, synthetic biology, regenerative medicine and digital-medicine R&D (up to CNY 2m/year per entity), platform/lab construction (up to 30% of investment, capped at CNY 2m), use of the district's translational-medicine national science facility (up to 50% of annual usage fee, capped at CNY 1m), and domestic Class 1 new-drug clinical trials (Phase I up to CNY 2m, Phase II up to CNY 5m, capped at CNY 50m/year per entity), plus annual support for biopharma industrial- park operators (up to CNY 2m/year).

Uruguay's Poder Ejecutivo promulgated Decreto Nº 329/025 on 23 December 2025, comprehensively overhauling the general investment-promotion framework established under Ley Nº 16.906 (1998) and replacing Decreto 268/020. Administered by COMAP under the Ministerio de Economía y Finanzas, the decree entered into force on 1 February 2026 with a coexistence transition period through 30 April 2026 and became the sole operative instrument from 1 May 2026. The decree extends project timelines, creates tiered investment categories (including a mega-investment tier providing up to 25-year IRAE exemptions), expands incentives for SMEs, and explicitly calibrates the scoring matrix toward decentralisation, innovation, export capacity, and strategic sectors including data-centers, green hydrogen, sustainable forestry-pulp, agtech, and global business services.

The European Investment Bank signed a EUR 90 million loan with METLEN Energy & Metals SA on 19 December 2025 (publicly announced 15 January 2026), financing modernisation of METLEN's bauxite mining operations in the Parnassus-Giona area and the construction of Europe's first EIB-financed gallium production line at the company's Aluminium of Greece complex in Agios Nikolaos, Viotia. The financing is provided under the REPowerEU framework and is explicitly framed by the EIB as supporting EU Critical Raw Materials Act (CRMA) objectives and reducing reliance on non-EU gallium supply. It is the third EIB financing extended to METLEN.

Section 851 of the FY 2026 National Defense Authorization Act (P.L. 119-60), signed December 18, 2025, prohibits US federal agencies from procuring biotechnology equipment or services from designated "biotechnology companies of concern" (BCCs), and bars federal contractors from using such equipment/services in work performed under federal contracts, grants, or loans. The final enacted text ties initial BCC designations to DoD's existing §1260H Chinese-military-company list (which currently includes BGI and MGI, but not WuXi AppTec or WuXi Biologics) and directs OMB to designate additional BCCs within one year of enactment; operational prohibitions activate 60-90 days after FAR revision, with a five-year grandfather period for pre-existing contracts — enforcement is expected to begin in 2027-28. The legislation is the successor to H.R.8333 (118th Congress, House-passed September 2024 but stalled in the Senate before adjournment) and represents the first enacted US federal-procurement biotech-supply-chain-resilience statute.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

In the early hours of 11 December 2025 the Council of the EU and the European Parliament reached provisional political agreement in trilogue on the "EU Pharma Package" — the revised pharmaceutical Regulation (COM 2023/0131) and Directive (COM 2023/0132) — the most significant overhaul of EU pharmaceutical legislation in over two decades. The package replaces Directive 2001/83/EC (Community Code on medicinal products for human use) and Regulation (EC) 726/2004 (the EMA Regulation), and consolidates the orphan-medicine (Regulation 141/2000) and pediatric-medicine regulations into a single framework. Headline provisions: (i) a new "8+1(+1)(+1)" IP-incentive architecture — 8 years of regulatory data protection plus 1 year of market protection, with up to two additional 12-month extensions for products addressing unmet medical need or new active substances meeting comparative-trial conditions, capped at 11 years total; (ii) an EU-wide list of critical medicines under enhanced governance via the Medicines Shortages Steering Group (MSSG) and an EMA "list of critical shortages in the EU"; (iii) mandatory shortage-prevention plans on marketing-authorisation holders for prescription medicines and Commission-designated products; (iv) modernisation of clinical-trial requirements, environmental-risk assessment, antimicrobial stewardship, and a transferable-exclusivity-voucher (TEV) regime to incentivise novel antibiotic R&D. The COREPER I committee endorsed the compromise text on 6 March 2026 and final adoption by Parliament and Council is expected during summer 2026, with the regulatory framework becoming applicable in 2028.

The UK government designated Russian media entity Rybar LLC and its director-general Mikhail Zvinchuk, alongside Aleksandr Dugin, the Foundation for the Support and Protection of the Rights of Compatriots Living Abroad (Pravfond), and affiliated entities Euromore, Golos, and the Center for Geopolitical Expertise, under the Russia (Sanctions) (EU Exit) Regulations 2019. The designations impose asset freezes and bans on commercial transactions and investment instruments with the named parties, on the basis that Rybar runs a foreign information manipulation and interference (FIMI) network promoting Russian state interests and destabilising Ukraine. Pravfond's network was separately alleged to have moved funds across at least 11 EU member states to fund pro-Kremlin media outlets while concealing state ties.

Singapore's National Research Foundation (NRF), under the Prime Minister's Office, launched the five-year Research, Innovation and Enterprise 2030 Plan on 5 December 2025, allocating S$37 billion (approximately 1% of GDP) for 2026-2030. The plan succeeds RIE2025 (S$25 billion) and introduces two named RIE Flagships and two RIE Grand Challenges; the first Flagship is in semiconductors and is explicitly aimed at making Singapore a strategically important R&D and manufacturing node in the global semiconductor supply chain. The budget envelope is split 24% foundational research, 20% innovation and enterprise, 17% infrastructure / new programmes ("white space"), 10% talent development.

The UK Department of Health and Social Care, delivered via Innovate UK, awarded more than GBP 54 million in government funding across eight R&D projects on 18 November 2025 through the Sustainable Medicines Manufacturing Innovation Programme, matched by more than GBP 20 million from industry (combined GBP 74m+). The programme is funded through the GBP 400 million VPAG Investment Programme, agreed under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), and supports the manufacturing pillar of the UK's Modern Industrial Strategy Life Sciences Sector Plan. Funded projects include anaesthetic gas recovery/recycling (targeting ~GBP 5m annual NHS savings), converting spent nuclear fuel into radionuclide cancer therapies, CAR-T cell manufacturing scale-up (Royal Free Hospital), engineered bacteriophages for antibiotic resistance, and an AstraZeneca-led "Sustainable Future Factory" AI/robotics initiative.

On 13 November 2025, the United States and the Republic of Korea released a Joint Fact Sheet reaffirming the July 2025 announcement of the Korea Strategic Trade and Investment Deal — the first standalone US-Korea trade-and-investment agreement since the 2012 KORUS FTA. USTR issued the implementing Federal Register notice (90 FR 55964, Notice 2025-21940) on 3 December 2025, effective 4 December 2025, with retroactive HTSUS application to 1 November 2025 for autos and auto parts and to 14 November 2025 for reciprocal-tariff goods, timber, lumber, derivatives, and certain aircraft and aircraft parts. On the US tariff side: (i) the country-specific IEEPA reciprocal tariff on Korean originating goods is set at the higher of the KORUS FTA / MFN rate or 15% (parallel to the Japan and EU framework deals); (ii) the Section 232 tariffs on autos, auto parts, timber, lumber and wood derivatives are reduced to 15% (no incremental duty when the pre-existing KORUS/MFN rate already meets or exceeds 15%); (iii) Korean exports of qualifying goods on the Potential Tariff Adjustments for Aligned Partners (PTAAP) list are exempt from reciprocal tariffs (covering generic pharmaceuticals and unavailable natural resources); (iv) Section 232 pharmaceuticals capped at 15%; semiconductors granted MFN-style "no less favourable" treatment in any future sectoral deal. On the investment side, Korea commits to a USD 350bn package: USD 150bn into US shipbuilding ("Approved Investments") plus USD 200bn into US strategic industries via a separate Strategic Investments MOU, with annual currency-funding cap of USD 20bn. Non-tariff commitments include streamlined US biotech approvals on the Korean side, US meat and cheese market access, fair treatment for US digital services, removal of Korea's 50,000-unit cap on US vehicles meeting FMVSS, and joint WTO support for the moratorium on customs duties on electronic transmissions.

Japan's Cabinet adopted a Cabinet Order on 11 November 2025 (promulgated 14 November 2025, effective 14 February 2026) amending Appended Table 1 of the Export Trade Control Order (輸出貿易管理令) to add three new list-control item categories: (i) peptide synthesizers and related components (Item group mapping to Australia Group 2023–2024 plenary dual-use biotechnology controls, aligning Japan with the US BIS implementation promulgated December 2024), (ii) powders of refractory metals or their alloys below specified particle-size and purity thresholds — tungsten, molybdenum, niobium, tantalum, and rhenium powders used as additive- manufacturing feedstocks (Item 5(20), implementing a Wassenaar Arrangement plenary outcome on metal-powder dual-use), and (iii) modules, assemblies, or devices incorporating field-programmable logic devices (FPGAs) above specified gate-count and process-node thresholds (Item 7(10-2), extending Japan's semiconductor-component AI-compute perimeter). This is the first discrete Appended Table 1 list-control amendment filed under the post-October-2025 FEFTA catch-all- controls overhaul architecture.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 54 million (~USD 35 million) equity stake in Synchron, a Melbourne-founded (now US-headquartered) brain-computer interface company, announced 7 November 2025. The investment forms part of Synchron's broader ~AUD 305-308 million (~USD 200 million) Series D raise alongside investors including Qatar Investment Authority, In-Q-Tel and Double Point Ventures, and is earmarked to fund final clinical trials and US FDA regulatory approval of Synchron's Stentrode device — a minimally-invasive BCI implanted via blood vessel without open brain surgery. NRFC frames the deal as commercialising Australian-origin technology and building sovereign medical-device manufacturing and clinical-trial capability.

The Chongqing Municipal People's Government General Office issued "Several Measures for Chongqing's Full-Chain Support of High-Quality Innovative Drug Development" (Yu Fu Ban Fa [2025] No. 56) on 2025-11-01, a 25-point package of regulatory-fast-track and procurement-support measures for the municipal biopharma sector. It targets 1-3 newly approved innovative drugs per year through 2027 (10 total) and the cultivation of 3 pharmaceutical-innovation industrial complexes, 3 high-level innovation platforms, and 3 innovative-drug industry clusters. No direct subsidy or tax-incentive amount is disclosed in the published text — the package is operational (compressed clinical-trial and registration timelines, guaranteed hospital procurement) rather than a cash grant.

On 28 October 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) signed five localization and knowledge-transfer agreements on the sidelines of the Global Health Exhibition 2025, covering domestic manufacture and technology transfer for the biologic drugs etanercept and adalimumab (both used to treat chronic inflammatory / autoimmune conditions) and for orthopedic trauma implants. The adalimumab agreement was signed separately with Boston Oncology Arabia and Tabuk Pharmaceuticals. Boston Oncology's own disclosure of its adalimumab/ etanercept agreement (announced 4 November 2025) put the combined economic impact at over SAR 1.2 billion in cumulative GDP contribution and approximately 500 direct jobs, with production sited at its Sudair Industrial City facility (USFDA/EMA/SFDA-standard). Global Trade Alert's tracking of the same state act records seven counterparties in total (Boston Oncology, Tabuk Pharmaceuticals, Rameem Medical, Bio Vision, Sudair Pharma, Almana Company, and an additional pharma manufacturer), consistent with LCGPA's practice of bundling several related product-localization signings into one event.

FinCEN issued a final rule under Section 311 of the USA PATRIOT Act (31 U.S.C. § 5318A) prohibiting US covered financial institutions from opening or maintaining a correspondent account for, or on behalf of, Cambodia-based Huione Group, a foreign financial institution found to be of primary money-laundering concern. Treasury determined that Huione Group and its subsidiaries — including Haowang Guarantee, Huione Pay PLC, and Huione Crypto — laundered at least $4 billion of illicit proceeds between August 2021 and January 2025, including funds tied to North Korean cyber-heist actors and Southeast Asian "pig-butchering" investment-scam compounds. The rule also imposes a special-due-diligence requirement on US covered institutions to guard against indirect access via foreign correspondent accounts. Effective November 17, 2025.

The UK Department for Science, Innovation and Technology and the Office for Life Sciences launched the Life Sciences Transformational R&D Investment Fund (TRIF) Pilot, a GBP 50 million (approx. USD 67.4 million) capital grant scheme for large-scale R&D projects in the life sciences sector. Only projects with total costs of at least GBP 100 million qualify, with grants typically covering 10-20% of total project costs. The pilot runs on a rolling-application basis until 31 March 2028 or until funding is exhausted.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 35 million (~USD 23.1 million) equity stake in Morse Micro, announced 23 September 2025. Morse Micro — described by NRFC as Australia's largest semiconductor manufacturer — designs Wi-Fi HaLow chips for long-range, low-power IoT connectivity, with a design and production hub in Picton, regional New South Wales. The investment forms part of Morse Micro's broader AUD 88 million Series C round, led by Japanese semiconductor designer MegaChips and joined by existing investors Blackbird, Main Sequence, and superannuation funds Hostplus, NGS and UniSuper. NRFC frames the deal as strengthening sovereign semiconductor manufacturing capability and supporting skilled jobs in regional NSW.

On 17 September 2025 the General Office of the Shanghai Municipal People's Government issued Hufubangui [2025] No. 8, a five-year (26 September 2025 - 25 September 2030) state-aid framework to accelerate frontier-technology innovation and cultivate "future industries" across six domains — future manufacturing, future information, future materials, future energy, future space and future health. Targeted technology areas include cell and gene therapy, brain-computer interfaces, biomanufacturing, embodied intelligence (humanoid robotics/AI hardware), fourth-generation semiconductors, silicon photonics, 6G, neuromorphic computing, quantum technology, controlled nuclear fusion and regenerative medicine. Support is disbursed as tiered direct subsidies rather than tax relief, with named ceilings up to CNY 30 million per proof-of-concept/R&D platform and CNY 20 million per high-quality incubator or first-product/batch innovation award.

The Bureau of Industry and Security (BIS) amended the Export Administration Regulations (EAR) to add 32 entities to the Entity List, with the largest bloc — 23 entries — under the destination of China, plus India (1), Iran (1), Singapore (1), Taiwan (1), Turkey (3), and the United Arab Emirates (2). The rule also removed two addresses from one Russian entry (Intertech Rus LLC) and made 27 typographical corrections to existing entries. Several Chinese additions — including Shanghai Fudan Microelectronics, Sino IC Technology, GMC Semiconductor (Wuxi), and Chinese Academy of Sciences units (National Time Service Center; Aerospace Information Research Institute) — were given footnote 4 designations, extending the EAR's foreign-direct-product (FDP) reach to non-US-origin items destined for Russian military end use. Three Turkish entries (Atempo, EB Teknoloji, Dentun Elektronik) and one Indian entry (AR Sales Pvt Ltd) were footnote-3 Russian Procurement Entity designations. The rule is a final rule effective September 12, 2025; all listed parties are subject to a license requirement for all items subject to the EAR with a presumption-of-denial review policy.

On 2025-09-12, Shanghai STAR Market-listed chip-equipment maker Piotech Inc. (拓荆科技, 688072.SH) disclosed a CNY 450 million (~USD 63 million) capital increase into its controlling subsidiary Piotech Jianke (Haining) Semiconductor Equipment Co., Ltd. (拓荆键科(海宁)半导体设备有限公司), which develops 3D-integration/hybrid-bonding equipment. Guotou Jixin (国投集新), a vehicle wholly owned (99.9%) by the National Integrated Circuit Industry Investment Fund Phase III ("Big Fund III"), took a 12.71% stake for roughly CNY 192 million, becoming Piotech Jianke's second-largest shareholder; Piotech's own stake fell to approximately 53.57% post-round. The round valued Piotech Jianke's pre-money equity at CNY 2.5 billion — a roughly 44x premium to its RMB 55.2 million book net-asset value as of 2024-12-31 — reflecting Big Fund III's first disclosed equity deployment since its 2024-05-24 establishment.

On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.

Brazil's Câmara de Comércio Exterior executive committee (Gecex) approved Resolução nº 779, de 28 de agosto de 2025, amending Annex V of the base tariff-nomenclature resolution (Gecex nº 272/2021). The resolution opens a new one-year, 25,000-tonne tariff-rate quota at a reduced 3.6% duty for chromium sulfate powder (NCM 2833.29.60), adds two natural-rubber lines (TSNR and granulated/pressed rubber, NCM 4001.22.00 / 4001.29.20) to the reduced-tariff annex at 10.8% with no volume cap, and simultaneously removes three antibiotic active-ingredient import lines — piperacillin/ tazobactam, ceftazidime, and meropenem (NCM 3004.10.19, 3004.20.59, 3004.20.99) — from the same reduced-tariff annex, reverting them to the standard (higher) MFN duty.

On 25 August 2025, Brazil's federal government launched a combined BRL 12 billion (~USD 2.2bn) subsidised credit line to fund the diffusion of Industry 4.0 machinery and equipment across the Brazilian industrial base. BNDES (national development bank) contributes BRL 10 billion nationwide through its "Crédito Indústria 4.0" line; Finep (research-financing agency) adds BRL 2 billion via its "Difusão Tecnológica" line, reserved for companies in the North, Northeast and Center-West regions to narrow regional investment gaps. Financing covers capital goods incorporating robotics, artificial intelligence, cloud computing, sensing, machine-to-machine communication and IoT, at concessional rates of roughly 7.5-8% plus spread; credit approvals began 15 September 2025. The line operates under the Nova Indústria Brasil (NIB) national industrial-policy framework.

On 22 August 2025 South Korea's National R&D Program Evaluation Steering Committee, convened by MOTIE, finalized an exemption from the mandatory preliminary feasibility study (예비타당성조사 면제) for the "K-On-Device AI Semiconductor Technology Development" project, clearing the roughly KRW 689.15 billion (approx. USD 496 million) program to proceed toward FY2026 budget allocation without the standard multi-year vetting delay. The project funds full-stack development — custom AI chip design, software, and modules — across four demand-anchored industries: automotive (Hyundai Motor), IoT/home appliances (LG Electronics), machinery/robotics (Doosan Robotics, Daedong), and defense (Korea Aerospace Industries). MOTIE structured the program so end-user demand companies participated directly in project planning, pairing them with domestic fabless design and foundry manufacturing firms to build a domestic on-device AI semiconductor ecosystem, ahead of full budget confirmation and formal program launch.

The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.

Banque des Territoires, acting on behalf of the French State under the France 2030 programme, launched a EUR 500 million fund-of-funds called "Global Tech Coté" on 7 August 2025. The vehicle takes minority stakes (EUR 15 million minimum, capped at 10% of a target fund's subscribed capital) in privately-managed investment funds that in turn back publicly-listed French technology companies with strong growth potential, aiming to build up domestic asset-management capacity alongside the state's stated goal of channelling capital into equities. The selection window for management companies runs until 31 December 2026 or until the EUR 500 million envelope is exhausted, whichever comes first.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

On 23 July 2025 the General Office of the Shanghai Municipal People's Government issued Hufu Bangui [2025] No. 5, "Several Measures to Support Enterprises in Strengthening Basic Research and Enhancing New Momentum for High-Quality Development," effective 1 August 2025 through 31 July 2030. The measure tiers one-time subsidies of CNY 2m-10m/year to enterprises based on basic-research investment (CNY 10m-50m, 50m-100m, and 100m+ investment bands), reimburses 50% of shared scientific- equipment usage fees (capped CNY 1m/year), and grants a 100% tax deduction for corporate donations to basic research at nonprofits and universities, with integrated circuits, biomedicine and artificial intelligence named as priority participating industries.

On 22 July 2025, BNDESPAR — the equity-investment arm of Brazil's national development bank BNDES — approved a BRL 114 million (approx. USD 20.5 million) minority equity subscription in Grupo Santa Clara, a Ribeirão Preto (São Paulo)-based producer of special fertilizers and bioinputs founded in 1997. The deal gives BNDESPAR a 19.9% stake, implying a company valuation near BRL 570 million, and is BNDESPAR's first direct variable-income (equity) operation since the bank reactivated its equity-participation strategy in June 2025 — a decade after its last direct stock investment. Proceeds are earmarked to expand Santa Clara's biofactory in Jaboticabal (SP) and fund the group's growth plan toward BRL 1 billion in revenue by 2030.

On 1 July 2025 India's Union Cabinet approved the Research Development and Innovation (RDI) Scheme, a six-year, ₹1,00,000 crore (≈USD 11.68 bn) fund to catalyse private-sector investment in research, development and innovation, with ₹20,000 crore allocated for FY2025-26. The scheme finances transformative RDI projects (TRL 4 and above) in strategic and sunrise sectors — deep tech, AI, biotechnology, quantum computing, robotics, space, energy transition and the digital economy — through long-tenor, low-or-nil-interest loans and equity, up to 50% of assessed project cost. Grants and short-term loans are explicitly excluded. Funds flow through a Special Purpose Fund under ANRF (first-level) to second-level fund managers — Alternate Investment Funds, Development Finance Institutions, NBFCs, and focused research bodies including the Technology Development Board (TDB) and BIRAC — which began issuing project calls in February 2026.

Vietnam's government issued Decree No. 160/2025/ND-CP establishing the National Data Development Fund, a non-budget state financial fund capitalised at VND 1 trillion (approx. USD 38.3 million). The fund, administered by the Ministry of Public Security, provides subsidised loans, interest-payment support, and grants — delegated through state-owned commercial and policy banks — to develop and protect data infrastructure and to support AI, big data, cloud computing, blockchain, and IoT projects serving state management and digital-transformation goals, with priority for rural and disadvantaged regions. The decree took effect 1 July 2025.

On 23 June 2025, BNDES president Aloizio Mercadante announced that BNDESPAR — the equity-investment arm of Brazil's national development bank — would resume direct variable-income (equity) investing after roughly a decade, committing up to BRL 10 billion (~USD 1.8bn) to companies and funds focused on ecological transition, decarbonization and innovation. The commitment splits into up to BRL 5 billion in direct equity investments (open to applicants through December 2025) and up to BRL 5 billion deployed via investment funds, funded from proceeds of BNDESPAR's sale of mature-company stakes and dividend receipts rather than new fiscal outlay. The bank framed the relaunch as strengthening Brazil's capital markets while directing state capital toward green-economy and innovation targets of all company sizes.

Slovakia's Office of the Deputy Prime Minister for the Recovery Plan and Knowledge Economy approved a EUR 160 million state-aid scheme ("Schéma štátnej pomoci na podporu znalostnej ekonomiky, výskumu, vývoja a inovácií") on 4 June 2025 to fund business-sector research, development and innovation projects, with emphasis on experimental development and industrial research. The office subsequently opened two calls under the scheme, in biotechnology and in robotics/automation, on 16 June 2025 (deadline 16 August 2025); demand of 338 project proposals worth over EUR 800 million led the office to raise the allocation for those two calls from EUR 180 million to roughly EUR 230 million. Supported projects run through 2027.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 27 million equity stake in PolyActiva, a Melbourne biotech developing a biodegradable ocular implant (Prezia/PA5108) that delivers glaucoma medication over 6-12 months as an alternative to daily eye drops. The investment, announced 30 May 2025, forms the majority of PolyActiva's AUD 40 million Series C round, with the remaining AUD 13 million from existing investor Brandon Capital. Funds will consolidate the company's R&D, analytics and manufacturing into a single Melbourne facility, grow its ~25-person workforce, and fund completion of a Phase 2b clinical trial, with commercialisation targeted for 2029.

The UK Department for Science, Innovation and Technology signed a grant agreement with BioNTech UK Ltd. providing up to GBP 129 million in government support over 10 years, underpinning BioNTech's planned GBP 1 billion (USD 1.3 billion) investment in UK research and development over the same period. The funding backs two new R&D hubs: a life-sciences research centre in Cambridge (genomics, oncology, structural biology, regenerative medicine) and an AI hub co-located with BioNTech's planned UK headquarters in London, run by its InstaDeep subsidiary. The government frames the deal as one of the largest single-company investments in UK life-sciences history and part of the Oxford-Cambridge Growth Corridor and Plan for Change industrial strategy.

President Trump signed Executive Order 14273, "Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients", on 12 May 2025. The EO directs HHS, USTR, and Commerce to pursue mechanisms (negotiation targets, importation pathways, and trade-policy levers) to bring the prices Americans pay for innovative prescription drugs into alignment with the *lowest* prices paid by other comparably-developed nations — the "most-favored-nation" (MFN) benchmark. Unlike the Biden-era Inflation Reduction Act drug-price-negotiation provisions (which apply to a handful of Medicare Part D drugs), the EO applies pressure across the broader pharmaceutical pricing surface. As of April 2026, 17 major pharmaceutical manufacturers (incl. Eli Lilly, Pfizer, Bristol-Myers Squibb, AbbVie, Merck, AstraZeneca, Regeneron) have signed bilateral agreements bringing US drug prices toward the international- benchmark level for selected medications.

On 30 April 2025 the General Office of the Guangdong Provincial People's Government issued Yue Fu Ban [2025] No. 11, "Several Measures of Guangdong Province to Further Stimulate Market Entity Vitality and Accelerate the Construction of a Modern Industrial System," effective immediately through 31 December 2027. The package subsidizes bank-loan interest for manufacturing and high-tech enterprises at up to 35% of the loan rate, capped at RMB 2 billion in total annual subsidy volume and RMB 20 million per enterprise per year, alongside an expansion of government-backed financing-guarantee coverage to over RMB 10 billion annually. It also funds foreign-invested R&D centers (up to RMB 1 million, or RMB 5 million for multinational global R&D centers) and offers headquarters-relocation bonuses of up to RMB 8 million, with priority given to semiconductors, AI, robotics, biotechnology, quantum technology, commercial aerospace, and new-energy vehicles.

Spain's Ministry of Industry and Tourism (MINCOTUR) provisionally approved EUR 90 million in grants across five industrial-decarbonisation projects under Line 4 of the PERTE Descarbonización (Spain's Recovery-and-Resilience-Plan-funded strategic decarbonisation programme). The largest award, EUR 60 million, went to Hydnum Puertollano (Ciudad Real) for a green-steel mill; other recipients were Biotérmica Villanueva (EUR 12m for a biomass plant converting orange waste to energy in Huelva, plus EUR 4.6m for an olive-pomace renewable-energy plant in Lebrija, Sevilla), Alier (EUR 9.6m, sustainable recycled-paper production in Zaragoza), and Cimsa Cementos España (EUR 3.7m, emissions reduction in Buñol, Valencia cement manufacturing). The announcement, made by Industry Minister Jordi Hereu on 23 April 2025, brought total PERTE Descarbonización disbursement to approximately EUR 570 million across 93 projects nationwide.